Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986090 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 26 May 2016
At a glance
- Drugs BMS 986090 (Primary) ; Hemocyanin
- Indications Immunological disorders
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 03 May 2016 Status changed from active, no longer recruiting to discontinued.
- 18 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Sep 2015 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016, as reported by ClinicalTrials.gov record.